Saleh et al’ s study showed that KEAP1 mutations accounted for about 17% of NSCLC patients, and KEAP1 mutation was significantly associated with higher age, male sex, adenocarcinoma differentiation and advanced stage, and also represented an independently negative prognostic biomarker [51]. The gene discussed is KEAP1; the disease is adenocarcinoma.